Logo image of VERA

VERA THERAPEUTICS INC (VERA) Stock Fundamental Analysis

NASDAQ:VERA - Nasdaq - US92337R1014 - Common Stock - Currency: USD

21.14  +0.97 (+4.81%)

After market: 21.14 0 (0%)

Fundamental Rating

2

Taking everything into account, VERA scores 2 out of 10 in our fundamental rating. VERA was compared to 550 industry peers in the Biotechnology industry. The financial health of VERA is average, but there are quite some concerns on its profitability. VERA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VERA has reported negative net income.
VERA had a negative operating cash flow in the past year.
VERA had negative earnings in each of the past 5 years.
VERA had a negative operating cash flow in each of the past 5 years.
VERA Yearly Net Income VS EBIT VS OCF VS FCFVERA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -37.73%, VERA perfoms like the industry average, outperforming 58.91% of the companies in the same industry.
With a decent Return On Equity value of -46.61%, VERA is doing good in the industry, outperforming 66.91% of the companies in the same industry.
Industry RankSector Rank
ROA -37.73%
ROE -46.61%
ROIC N/A
ROA(3y)-48.55%
ROA(5y)-56.49%
ROE(3y)-78.86%
ROE(5y)-77.96%
ROIC(3y)N/A
ROIC(5y)N/A
VERA Yearly ROA, ROE, ROICVERA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

VERA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VERA Yearly Profit, Operating, Gross MarginsVERA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for VERA has been increased compared to 1 year ago.
Compared to 5 years ago, VERA has more shares outstanding
VERA has a better debt/assets ratio than last year.
VERA Yearly Shares OutstandingVERA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
VERA Yearly Total Debt VS Total AssetsVERA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

VERA has an Altman-Z score of 5.34. This indicates that VERA is financially healthy and has little risk of bankruptcy at the moment.
VERA has a Altman-Z score of 5.34. This is in the better half of the industry: VERA outperforms 78.18% of its industry peers.
VERA has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.16, VERA is not doing good in the industry: 67.82% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Altman-Z 5.34
ROIC/WACCN/A
WACCN/A
VERA Yearly LT Debt VS Equity VS FCFVERA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

VERA has a Current Ratio of 17.03. This indicates that VERA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 17.03, VERA belongs to the top of the industry, outperforming 91.45% of the companies in the same industry.
VERA has a Quick Ratio of 17.03. This indicates that VERA is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of VERA (17.03) is better than 91.64% of its industry peers.
Industry RankSector Rank
Current Ratio 17.03
Quick Ratio 17.03
VERA Yearly Current Assets VS Current LiabilitesVERA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for VERA have decreased strongly by -19.05% in the last year.
EPS 1Y (TTM)-19.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-94.8%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 32.78% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-21.46%
EPS Next 2Y-12.67%
EPS Next 3Y4.35%
EPS Next 5Y32.78%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VERA Yearly Revenue VS EstimatesVERA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
VERA Yearly EPS VS EstimatesVERA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VERA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VERA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VERA Price Earnings VS Forward Price EarningsVERA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VERA Per share dataVERA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.67%
EPS Next 3Y4.35%

More info and screens

0

5. Dividend

5.1 Amount

VERA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERA THERAPEUTICS INC

NASDAQ:VERA (8/12/2025, 8:21:17 PM)

After market: 21.14 0 (0%)

21.14

+0.97 (+4.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners111.59%
Inst Owner Change-0.25%
Ins Owners1.05%
Ins Owner Change2.48%
Market Cap1.35B
Analysts84
Price Target67.83 (220.86%)
Short Float %13.57%
Short Ratio4.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.53%
PT rev (3m)0.87%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.43%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.88
P/tB 2.88
EV/EBITDA N/A
EPS(TTM)-2.75
EYN/A
EPS(NY)-3.49
Fwd EYN/A
FCF(TTM)-2.93
FCFYN/A
OCF(TTM)-2.91
OCFYN/A
SpS0
BVpS7.34
TBVpS7.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.73%
ROE -46.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.55%
ROA(5y)-56.49%
ROE(3y)-78.86%
ROE(5y)-77.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 451.59%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.03
Quick Ratio 17.03
Altman-Z 5.34
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-94.8%
EPS Next Y-21.46%
EPS Next 2Y-12.67%
EPS Next 3Y4.35%
EPS Next 5Y32.78%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-101.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-32.62%
EBIT Next 3Y12.29%
EBIT Next 5YN/A
FCF growth 1Y-122.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-121.48%
OCF growth 3YN/A
OCF growth 5YN/A